A Study of Stavudine in HIV-Infected Patients Who Have Not Had Success With Other Anti-HIV Drugs

Inclusion Criteria Patients must have: * HIV positivity with CD4 count \< 300 cells/mm3. * Intolerance to or failure on approved antiretroviral therapy. * Ability to provide informed consent (of parent or guardian if appropriate). NOTE: * Incarcerated persons may be eligible to participate. Exclusion Criteria Co-existing Condition: Patients with the following symptoms or conditions are excluded: * Grade 2 or worse disease-related peripheral neuropathy. * Unresolved drug-related peripheral neuropathy of any severity that is attributable to other nucleoside analogs (AZT, ddC, ddI). * Malignancy likely to require systemic chemotherapy with myelosuppressive or neurotoxic drugs in the first 3 months of stavudine treatment. * Pregnancy (physicians of pregnant patients may contact Bristol-Myers to determine eligibility for stavudine therapy in another protocol). Strongly discouraged: * AZT, ddI, ddC, and other antiretroviral agents.